Kornimate/medical-research-clean huggingface dataset:
does vascular endothelial growth factor (vegf) or complement factor h gene polymorphism play a role in the treatment success with vegf inhibitors in patients with choroidal neovascularization (cnv)?

Conditions: Choroidal NeoVascularization; Age-Related Macular Degeneration

Summary: age related macular degeneration (amd) is a multifactorial disease with a strong genetic component. most importantly a genetic polymorphism in the gene encoding for the complement factor h (cfh) has been recently identified which is highly associated with an increased risk of developing amd. this tyr402his polymorphism located on chromosome 1q31 has been implicated to play a role in the development of the disease. for this purpose a total of 200 patients with wet amd will be included in the study. as described in detail below, the current study aims to identify potentially non-responders to anti-vegf therapy based on genetic analysis of vegf polymorphism and complement factor h polymorphism.


Eligibility criteria:
inclusion criteria: * men and women aged over 50 years * angiographically verified neovascular amd * active primary or recurrent subfoveal lesion with cnv secondary to amd * activity to be proven by fluorescein angiography * best corrected visual acuity assessed using etdrs charts of 20/40 to 20/320 in the study eye * cnv to be treated with intravitreal ranibizumab * signed informed consent exclusion criteria: * prior treatment with any intravitreal drug in the study eye * prior treatment with verteporfin photodynamic therapy in the study eye * prior treatment with systemic bevacizumab * prior treatment with any intravitreal drug or verteporfin photodynamic therapy in the non-study eye within the 3 moths before the study entry * laser photocoagulation within 1 month before study entry in the study eye * previous participation in any clinical trial within 1 month before the entry of the study * subfoveal fibrosis or atrophy in the study eye * cnv in either of the two eye due to causes other than amd such as histoplasmosis or pathological myopia * retinal pigment epithelial tear involving the macula in the study eye * any concurrent intraocular condition in the study eye that could either require medical or surgical intervention during the 12 month study period or that could contribute to a loss of best corrected visual acuity over the 12 months study period (e.g. diabetic retinopathy, cataract, uncontrolled glaucoma). the decision on exclusion is to be based on the opinion of the local principal investigator. * active intraocular inflammation * acute angle-closure glaucoma or narrow angle glaucoma due to the risk of iop elevation caused by the administration of tropicamide

Keywords: amd vegf genotyping complement h gene polymorphism vascular endothelial growth factor a
effect of presenting survival information as text or pictograph during periviable birth counseling

Conditions: Premature Birth

Summary: women recruited from the internet will be put in a hypothetical situation of being in labor at 22 weeks of pregnancy, and presented with information on the likelihood of survival and chance of disability for babies born at this gestational age. participants will be randomized to receive this outcome data in one of three formats: as text-only, in a static pictograph, or in an iterative pictograph. participants will also be randomized to seeing the chance of survival as 30% or 60%. participants were then asked to choose between comfort care and intensive care in this situation. participants' religiosity, value of the sanctity of life, and health literacy were also assessed.

a recent study by kidszun et al. (2020) concluded that for mothers placed in a hypothetical situation of choosing between comfort care and intensive care at 22 weeks gestation, treatment choice was not influenced by the chance of survival. specifically, there was no difference in treatment choice between moms who were told the baby would have a 30% chance of survival and moms who were told the baby would have a 60% chance of survival. the study was conducted using a written vignette that included a paragraph on the chance of survival and the chance of disability among the survivors. in this study, we will adapt the vignette the kidszun et al. (2020) team used, and provide it to an internet-based sample of women. in this vignette, participants will be put in a hypothetical situation of being in labor at 22 weeks of pregnancy, provided a description of the treatment choices of intensive care or comfort care, and provided data on outcome information at this gestational age. after reading the vignette, participants will be randomized to view either: a repeat of the text information on outcome data, a static pictograph, or an iterative pictograph. participants will also be randomized to seeing the chance of survival as 30% or 60%, making this a 2 (chance of survival) x 3 (data presentation format) between-subjects experiment. after viewing a repeat of the outcome information, participants will be asked to choose between intensive care or comfort care for their hypothetical child. we will also collect information on values, religiosity, health literacy, subjective numeracy, a subjective probability estimate, and demographics.

Eligibility criteria:
inclusion criteria: women who have: * had a child, * are currently of child-bearing age (defined as 18-45) * and who live in the u.s. exclusion criteria: * minors * those unable to read english * those who only could complete the survey on their phone. (for formatting purposes, a tablet or computer is necessary.)

Keywords: decision making neonatal resuscitation risk communication prenatal counseling
assessment of dermatologic family impact scale in the parents of children with psoriasis

Conditions: Psoriasis; Quality of Life

Summary: the dermatological diseases family impact scale (defis) was developed to assess different aspects of health-related quality of life in the relatives of the patients with various skin diseases. the preliminary validation of this instrument was performed for the turkish population. in the pilot study, this 15-item-questionnaire was shown to be easy to complete and score, and reliably help to evaluate the family members' quality of life. psoriasis is a chronic disease which can be expected to have a significant impact on the quality of life of the patients and parents/family members alike. in line with this assumption, previous studies demonstrated that psoriasis psychosocially affects not only the patients, but also their close relatives. the psoriasis family index has been developed in an effort to objectively measure the health-related quality of life of the family members of patients with psoriasis. nevertheless, data regarding the health-related quality of life of the parents of pediatric patients with psoriasis in the turkish population are relatively scarce. in study, the investigators primarily aim to utilize defis to assess the impact of childhood psoriasis on the quality of life of the patients' parents. further, the investigators attempt to investigate the relation between the quality of life of the patients and their parents, and reveal disease characteristics which might influence the quality of life.


Eligibility criteria:
inclusion criteria: * pediatric patients diagnosed with psoriasis by the dermatologists within the study period exclusion criteria: * patients with an equivocal diagnosis * parents unable to complete the questionnaire * patients with a serious medical disorder or in an emergency condition
conventional direct laryngoscopy vs. video laryngoscopy with the c-mac for pyloromyotomy

Conditions: Pyloric Stenosis; Intubation, Pediatric

Summary: the purpose of this study is to compare two different ways of placing breathing tubes for surgery. both ways are used currently to place breathing tubes and are safe and effective. this study seeks to determine if one way is better than the other for infants with pyloric stenosis.

specific aims of this study include determining if there is a difference in the desaturation rates of the two different intubation techniques- direct laryngoscopy and the c-mac video laryngoscope. also is there a difference in intubation success between the two techniques, does intubation success vary with different training levels, and does desaturation rate differ among training levels.

Eligibility criteria:
inclusion criteria: * need general anesthesia for pyloromyotomy procedure * have been informed of the nature of the study and informed consent has been obtained from the legally responsible guardian exclusion criteria: * abnormal/difficult airway * allergy to succinylcholine and/or propofol

Keywords: storz c-mac direct laryngoscopy pyloromyotomy rapid sequence
transbronchial mwa for pulmonary tumors

Conditions: Lung Cancer

Summary: the purpose of the study is to evaluate the efficacy and safety of transbronchial microwave ablation for lung cancer.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years old; 2. pathologically diagnosed as primary peripheral lung cancer, preoperative staging suggested clinical staging as t1n0m0, stage ia (including new-onset lung cancer after surgery and multiple primary lung cancer). or it is a metastatic lung tumor, the primary lesion has been completely resected, and the maximum diameter of the tumor is ≤3cm, the number of tumors requiring intervention is ≤3. 3. the lesion to be ablated has been evaluated as feasible for microwave ablation treatment under bronchoscopy guidance. 4. agree to undergo transbronchial mwa as initial treatment after being assessed unsuitable for surgery and radiotherapy or refusing surgery and radiotherapy, and sign informed consent. exclusion criteria: 1. diffuse lesions in both lungs, for which ablation therapy is ineffective; 2. preoperative evaluation within one month reveals the presence of intrathoracic lymph node metastasis or extrapulmonary metastasis (excluding cases where extrapulmonary metastasis has been locally controlled); 3. contraindications to bronchoscopy, or inability to tolerate or comply with bronchoscopic procedures; 4. severe hemorrhagic tendency, or uncorrectable coagulation disorders (pt \> 18 seconds, pta \< 40%); 5. platelet count \< 70 × 10\^9/l, or ongoing anticoagulant and/or antiplatelet therapy that has not been discontinued for more than one week prior to ablation (with the exception of prophylactic low-molecular-weight heparin use); 6. severe pulmonary function impairment, with a maximal ventilatory volume \< 40%; 7. concurrent malignancies with widespread metastasis, with an expected survival of less than three months; 8. poor overall condition (including widespread metastasis, severe infection, high fever), infectious or radiation-induced inflammation surrounding the lesion, significant cachexia, severe organ dysfunction, severe anemia, or nutritional and metabolic disturbances that cannot be corrected in the short term; 9. eastern cooperative oncology group (ecog) performance status score \> 2 ; 10. lesions planned for ablation have received radiotherapy within the past six months; 11. active hepatitis b, active hepatitis c, known human immunodeficiency virus (hiv) infection (hiv-1/2 antibody positive), or other active infections that may impact the patient's ability to undergo treatment as determined by the investigator; 12. history of epilepsy, psychiatric disorders, or cognitive impairments; 13. patients with implanted cardiac pacemakers; 14. patients wearing metal jewelry or clothing with metallic components; 15. pregnant or lactating women, and individuals planning to conceive or become pregnant during the study period; 16. participation in any other clinical trial within three months prior to signing the informed consent form (non-interventional studies excluded); 17. any other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
to validate the specific patterns of magnetocardiography, a non-invasive non-contact examination for patients with ischemic heart disease or cardiac arrhythmia

Conditions: Arrhythmia

Summary: ecg is one of the most important non-invasive method to diagnose cad and arrhythmia. however, clinically it still has its limitation. because the electrical field could induce a magnetic field, the newly developed non-contact technique, magnetocardiography, was established to detect the local magnetic field component of the heart. it is safe and more convenient. in this study, we try to define and validate the magnetocardiographic patterns in the patients with cardiac arrhythmias or ischemia.


Eligibility criteria:
patient enrollment: * patients older than 18 years old, * having received 1) 12-lead ecg examination for suspected cardiac arrhythmias or 2) stress tests for suspected coronary artery disease, will be invited. * the patients who have medical devices made of metallic or magnetic material (ex. pacemaker, mechanical valve and arthroplasty) will be excluded to prevent the experimental bias.

Keywords: diagnose cardiac arrhythmia and cad. we'll try to establish the specific model to detect and diagnose cardiac arrhythmia and cad.
lycopene in preventing prostate cancer in healthy participants

Conditions: Prostate Cancer

Summary: rationale: chemoprevention is the use of certain drugs or substances to keep cancer from forming, growing, or coming back. the use of lycopene, a substance found in tomatoes, may keep prostate cancer from forming. purpose: this randomized clinical trial is studying how well lycopene works in preventing prostate cancer in healthy participants.

objectives: primary * determine whether lycopene supplementation affects percent free and bound prostate-specific antigen (psa) in healthy participants. secondary * determine whether lycopene reduces oxidative stress in these participants, as indicated by lipid peroxidation assay. * determine whether a 21-day washout period is sufficient to return lycopene, psa, and lipid peroxidation products to baseline. outline: this is a randomized, placebo-controlled study. participants are randomized to 1 of 3 treatment arms. * arm i: participants receive an oral tomato dietary supplement containing lycopene twice daily for 3 weeks. * arm ii: participants receive an oral tomato dietary supplement containing lycopene at a higher dose twice daily for 3 weeks. * arm iii: participants receive oral placebo twice daily for 3 weeks. urine and blood samples are collected on days 0, 21, and 42. projected accrual: a total of 150 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * healthy participants * no existing prostate disease patient characteristics: * able to supply blood and urine samples * able to answer demographic and dietary recall questionnaires * no hospital inpatients * not allergic to tomatoes or tomato products * not abusing alcohol or non-prescribed drugs * no existing gastrointestinal disease or cancer prior concurrent therapy: * at least 2 weeks since prior lycopene (in supplement form) * no concurrent participation in another clinical trial

Keywords: prostate cancer
like father like son

Conditions: Health Knowledge, Attitudes, Practice; Health Risk Behaviors

Summary: this purpose of this study is to look at the best way to offer the like father like son + spear \& shield program.


Eligibility criteria:
inclusion criteria: * men and women must be able to understand and sign the informed consent in english or local language. * all participants must be adults able to provide consent * women participants may be pregnant * individuals not yet adults (infants, children, teenagers) are not eligible to participate * prisoners will not be eligible for recruitment exclusion criteria: - participants not meeting any of the inclusion criteria.

Keywords: early infant male circumcision hiv infection
impact of p53 and sirt1 in type 2 diabetes

Conditions: DM

Summary: investigating the impact of p53 and sirt1 in the development of type 2 dm

investigating the impact of p53 and sirt1 in the development of type 2 dm through the treatment of prediabetic individuals by either nigetella salivata or metformin

Eligibility criteria:
inclusion criteria: * prediabetic subjects. exclusion criteria: * confirmed diabetes. * hepatic or renal impairment.
the plasma diafiltration therapy of hepatic failure

Conditions: Hepatic Failure; Plasma Exchange

Summary: at present, there is no comparative study between the simple plasma exchange and plasma diafiltration (pdf), and no further exploration of optimal plasma dose in pdf treatment. therefore, this prospective randomized cohort study aims to compare the safety and effectiveness of the tree groups（simple plasma exchange group, conventional pdf treatment group, less plasma pdf treatment group）by collecting sofa score, 3-month survival rate, meld score, and the times of artificial liver treatment , blood cell variables, cytokines(e.g. tnfα ), pre- and post-treatment plasma ammonia levels. thus, it is to provide a safer and more effective artificial liver treatment with less plasma dose.


Eligibility criteria:
inclusion criteria: * hepatic failure on medium period * model for end-stage liver disease (meld) \ 20 * age \> 18 years and \<70years * written informed consent exclusion criteria: * active bleeding or disseminated intravascular coagulation * allergic to blood products or drugs such as plasma, heparin and protamine * hemodynamic instability * cardiovascular and cerebrovascular accidental infarction instability period * extravascular hemolysis * severe sepsis * tumor on ultrasonography, ct or mri examination * pregnant or lactating women
randomized trial of vitamin a and vitamin e supplementation for retinitis pigmentosa

Conditions: Retinitis Pigmentosa

Summary: to determine whether supplements of vitamin a or vitamin e alone or in combination affect the course of retinitis pigmentosa.

retinitis pigmentosa (rp) is a group of inherited retinal degenerations with a worldwide prevalence of about 1 in 4,000. patients typically report night blindness in adolescence and lose vision in the midperipheral followed by far-peripheral visual field in adulthood due to progressive loss of both rod and cone function. most patients have reductions in central vision by age 50 to 80 years. modern-day electroretinograms (ergs) make it possible to record retinal responses from most patients with remaining vision and thereby monitor objectively the course of their disease. while the natural course of retinal degeneration in the common forms of rp was being studied, it was noted that a subgroup of patients aged 18 through 49 who were treating themselves with both vitamin a and vitamin e and other nutritional supplements exhibited less decline in erg amplitude over a 2-year period. these preliminary findings, as well as the known roles of vitamins a and e in maintaining normal photoreceptor function and structure, prompted this randomized, controlled trial to determine whether these vitamins alone or in combination would halt or slow the progression of the common forms of rp. this study was a randomized, controlled double-masked trial with 2 x 2 factorial design and duration of 4 to 6 years. patients were assigned to one of four treatment groups: 15,000 iu/day vitamin a 15,000 iu/day vitamin a + 400 iu/day vitamin e trace amounts of both vitamins a and e 400 iu/day of vitamin e the main outcome measure was the 30-hz cone erg amplitude. in addition, visual field and visual acuity were measured annually.

Eligibility criteria:
men and nonpregnant women between ages 18 and 49 years with common forms of rp were included. all eligible patients had retinal arteriolar attenuation, elevated dark adaptation thresholds, and reduced ergs. patients had best corrected snellen visual acuity of 20/100 or better, central visual field diameter on the goldman perimeter with v4 e white test light of 8 degrees or greater, and erg amplitude of 2.5 or greater in response to 0.5-hz white light or of 0.12 ultraviolet light or greater in response to 30-hz white flickering light in at least one eye. in addition, patients had normal fasting serum retinol and serum liver function profile and weight above the lower fifth percentile for age, sex, and height. all patients had a total estimated pre-trial intake of vitamins a and e from diet plus pills not greater than 11,500 iu/day and 40 iu/day, respectively.

Keywords: retinitis pigmentosa vitamin supplements
stromal therapy of osteodysplasia after allogeneic bone marrow transplantation

Conditions: Osteodysplasia

Summary: osteodysplasia or poorly formed bones, "brittle bones" is a genetic disease with no known proven treatments. some forms of osteodysplasia may cause severe disability and even death. eligible patients were limited to those children with osteodysplasia who had undergone a previous allogeneic bone marrow transplant at st. jude. the study intervention involved an infusion of a specified number of ex vivo expanded stromal cells obtained from the bone marrow of the same donor from whom they received their primary transplant procedure. these bone marrow stromal cells can become bone-forming cells, called osteoblasts. participants then received 2 infusions of ex vivo expanded, gene marked cells not less than 6 months after bone marrow transplantation. the second cell infusion occurred between 14 to 21 days after the first infusion in the absence of toxicity. the goal of the study was to evaluate the safety and toxicity of these infusions.

* to determine whether these ex vivo expanded, gene marked marrow stromal cells will engraft in the recipient's bone, bone marrow, and/or skin. * to begin to investigate whether high proliferative mesenchymal progenitor cells can be expanded ex vivo and retain their progenitor potential in vivo. * to begin to investigate whether ex vivo expanded bone marrow stromal cells can ameliorate the skeletal dysplasias associated with various genetic disorders.

Eligibility criteria:
inclusion criteria: * patients with an appropriate genetic disorder who have had an allogeneic bone marrow transplant and currently maintain complete or mixed hematopoietic chimerism * patient must be \< or equal to 18kg exclusion criteria: * presence of infection * presence of gvhd (graft versus host disease)or the need for prophylaxis * concurrent participation in any investigational study that could potentially confound the interpretation of the safety parameters being investigated in this study.

Keywords: bone marrow transplant bone marrow stromal cells allogeneic transplant osteodysplasia osteogenesis imperfecta gene marking stromal cell
is ultrasonography comparable to mri for the detection of morton neuroma of the foot?

Conditions: Morton Neuroma

Summary: patients with morton neuroma of the foot will undergo either ultrasonography or mri. the results will be compared. in case of surgery, the pathology report will be compared with the ultrasonographic or mri findings. which is the most reliable and specific: ultrasonography or mri?


Eligibility criteria:
inclusion criteria: * morton neuroma of the foot exclusion criteria: -